Huayao’s Biotech Empire Soars: October Revenue Skyrockets 60% to Record High

Huayao (6446), the king of biotech drugs, announced today (5th) that its revenue in October was 910 million yuan, a monthly decrease of 2.4% and an annual increase of 67.02%. cancer drug Ropeginterferon alfa-2b (Ropeg) in the US Sales are the main focus, and market performance in the US and Japan continues to grow. This year’s cumulative revenue has reached 7.59 billion yuan, an annual increase of 89.4%.

Yaohua Pharmaceutical announced revenue of 910 million yuan in October, a monthly decrease of 2.4% and an annual increase of 67.02%, setting a new high for the same period. Photo/Yahoo stock market (krisanapong detraphiphat via Getty Images)

Yaohua Pharmaceutical said its self-developed Ropec has experienced steady growth in global sales since its launch. Yaohua Pharmaceutical stated that the US FDA target date (PDUFA date) for completion of the review of Ropeg’s head spray application (sBLA) is January 10, 2025. The company is looking forward to bringing this product to the market as quickly as possible to meet patient needs. In addition, the US subsidiary has started to analyze business data to make more complete plans for further development, together with the new US leadership team taking full advantage of its strengths and ensuring efficient cooperation, it is expected that the scope of Ropeg in the United States continues. to increase.

The team of Japanese subsidiary Yaohua Pharmaceutical launched a home drug delivery service on October 1 to further facilitate patient access to medicines. This new service has begun to develop steadily, driving continued revenue growth in Japan.

In terms of clinical trials, the global phase III clinical trial of Ropeg for essential thrombocythemia (ET) is expected to have top-line results as soon as the end of this year to the beginning of next year; 3 clinical trial design for primary myelofibrosis or overt primary myelofibrosis (PMF) of low or intermediate risk grade 1 approved by PMDA Japan.

Yaohua Medicine mentioned that in recent years, solid tumor treatment has gradually become the mainstream of cell therapy, especially T-cell receptor (TCR-T) immunotherapy, which has technical obstacles and high cost, and has attracted special attention. This therapy genetically modifies the patient’s T cells in vitro so that they have the ability to correctly recognize and attack tumor cells.

⭐Join the Hand Knife! The official account of Yahoo Line’s financial management⭐